Stock HLUN B H. LUNDBECK A/S
Add to a list
To use this feature you must be a member
Log inSign up

Highlights H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Market Closed - Nasdaq Copenhagen
Other stock markets
 11:20:00 2024-06-28 EDT 		5-day change 1st Jan Change
38.86 DKK +1.99% Intraday chart for H. Lundbeck A/S +0.41% +18.62%
06-26 Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application MT
06-25 US FDA Accepts Lundbeck, Otsuka's New Drug Application for PTSD Combo Treatment MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
US FDA Accepts Lundbeck, Otsuka's New Drug Application for PTSD Combo Treatment
MT
Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder
CI
H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial
CI
Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia
CI
H LUNDBECK : Q1 beat adds momentum to the recent share price rally
Alphavalue
H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
H. Lundbeck A/S Provides Earnings Guidance for the Year 2024
CI
H LUNDBECK : Lundbeck is well-poised to sail through the transition period
Alphavalue
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy
MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
CI
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia
MT
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia
CI
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023
CI
H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage
CI
H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HLUN B Stock
  4. News H. Lundbeck A/S
  5. Highlights